375 related articles for article (PubMed ID: 33328604)
1. Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.
Dong B; Miao J; Wang Y; Luo W; Ji Z; Lai H; Zhang M; Cheng X; Wang J; Fang Y; Zhu HH; Chua CW; Fan L; Zhu Y; Pan J; Wang J; Xue W; Gao WQ
Commun Biol; 2020 Dec; 3(1):778. PubMed ID: 33328604
[TBL] [Abstract][Full Text] [Related]
2. The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
Dankert JT; Wiesehöfer M; Czyrnik ED; Singer BB; von Ostau N; Wennemuth G
PLoS One; 2018; 13(7):e0200472. PubMed ID: 30001402
[TBL] [Abstract][Full Text] [Related]
3. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
4. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1β promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features.
Liu Q; Russell MR; Shahriari K; Jernigan DL; Lioni MI; Garcia FU; Fatatis A
Cancer Res; 2013 Jun; 73(11):3297-305. PubMed ID: 23536554
[TBL] [Abstract][Full Text] [Related]
6. [Neuroendocrine differentiation in prostate cancer].
Wu CY; Na YQ; Yao JL; di Sant'Agnese PA; Huang JT
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):565-7. PubMed ID: 17134555
[No Abstract] [Full Text] [Related]
7. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation of prostate cancer.
Li Z; Chen CJ; Wang JK; Hsia E; Li W; Squires J; Sun Y; Huang J
Asian J Androl; 2013 May; 15(3):328-32. PubMed ID: 23503426
[No Abstract] [Full Text] [Related]
9. Isoform 1 of TPD52 (PC-1) promotes neuroendocrine transdifferentiation in prostate cancer cells.
Moritz T; Venz S; Junker H; Kreuz S; Walther R; Zimmermann U
Tumour Biol; 2016 Aug; 37(8):10435-46. PubMed ID: 26846108
[TBL] [Abstract][Full Text] [Related]
10. EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers.
Soundararajan R; Paranjape AN; Maity S; Aparicio A; Mani SA
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):229-238. PubMed ID: 29981816
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.
Puca L; Vlachostergios PJ; Beltran H
Cold Spring Harb Perspect Med; 2019 Feb; 9(2):. PubMed ID: 29844220
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine transdifferentiation of prostate carcinoma cells and its prognostic significance.
Marcu M; Radu E; Sajin M
Rom J Morphol Embryol; 2010; 51(1):7-12. PubMed ID: 20191113
[TBL] [Abstract][Full Text] [Related]
13. Gelsolin Governs the Neuroendocrine Transdifferentiation of Prostate Cancer Cells and Suppresses the Apoptotic Machinery.
Oelrich F; Junker H; Stope MB; Erb HHH; Walther R; Venz S; Zimmermann U
Anticancer Res; 2021 Aug; 41(8):3717-3729. PubMed ID: 34281830
[TBL] [Abstract][Full Text] [Related]
14. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer.
Wu C; Wyatt AW; Lapuk AV; McPherson A; McConeghy BJ; Bell RH; Anderson S; Haegert A; Brahmbhatt S; Shukin R; Mo F; Li E; Fazli L; Hurtado-Coll A; Jones EC; Butterfield YS; Hach F; Hormozdiari F; Hajirasouliha I; Boutros PC; Bristow RG; Jones SJ; Hirst M; Marra MA; Maher CA; Chinnaiyan AM; Sahinalp SC; Gleave ME; Volik SV; Collins CC
J Pathol; 2012 May; 227(1):53-61. PubMed ID: 22294438
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine tumors of the prostate.
Fine SW
Mod Pathol; 2018 Jan; 31(S1):S122-132. PubMed ID: 29297494
[TBL] [Abstract][Full Text] [Related]
16. De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah E; Reichert ZR; Davenport MS; Chinnaiyan AM; Dadhania V; Wang X; Mannan R; Kunju LP; Hollenbeck BK; Montgomery JS; Kaffenberger SD; Morgan TM; Alva AS; Palapattu GS; Vaishampayan UN; Alumkal JJ; Spratt DE; Udager AM; Mehra R
Med Oncol; 2021 Feb; 38(3):26. PubMed ID: 33586037
[TBL] [Abstract][Full Text] [Related]
17. A basal stem cell signature identifies aggressive prostate cancer phenotypes.
Smith BA; Sokolov A; Uzunangelov V; Baertsch R; Newton Y; Graim K; Mathis C; Cheng D; Stuart JM; Witte ON
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6544-52. PubMed ID: 26460041
[TBL] [Abstract][Full Text] [Related]
18. FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer.
Han M; Li F; Zhang Y; Dai P; He J; Li Y; Zhu Y; Zheng J; Huang H; Bai F; Gao D
Cancer Cell; 2022 Nov; 40(11):1306-1323.e8. PubMed ID: 36332622
[TBL] [Abstract][Full Text] [Related]
19. Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.
Zamora I; Freeman MR; Encío IJ; Rotinen M
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37761978
[TBL] [Abstract][Full Text] [Related]
20. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
